[HTML][HTML] Targeting HER2-positive breast cancer: advances and future directions
SM Swain, M Shastry, E Hamilton - Nature reviews Drug discovery, 2023 - nature.com
The long-sought discovery of HER2 as an actionable and highly sensitive therapeutic target
was a major breakthrough for the treatment of highly aggressive HER2-positive breast …
was a major breakthrough for the treatment of highly aggressive HER2-positive breast …
[HTML][HTML] Advances in dendritic cell vaccination therapy of cancer
S Najafi, K Mortezaee - Biomedicine & Pharmacotherapy, 2023 - Elsevier
Traditionally, vaccines have helped eradication of several infectious diseases and also
saved millions of lives in the human history. Those prophylactic vaccines have acted through …
saved millions of lives in the human history. Those prophylactic vaccines have acted through …
[HTML][HTML] Dendritic cell vaccines in breast cancer: Immune modulation and immunotherapy
D Qian, J Li, M Huang, Q Cui, X Liu, K Sun - Biomedicine & …, 2023 - Elsevier
Breast cancer (BC) is the most common cancer in women worldwide. Although substantial
progress has been made in the diagnosis and treatment of breast cancer, the efficacy and …
progress has been made in the diagnosis and treatment of breast cancer, the efficacy and …
Theranostic chimeric antigen receptor (CAR)-T cells: Insight into recent trends and challenges in solid tumors
K Kheyrolahzadeh, MR Tohidkia, A Tarighatnia… - Life Sciences, 2023 - Elsevier
Cell therapy has reached significant milestones in various life-threatening diseases,
including cancer. Cell therapy using fluorescent and radiolabeled chimeric antigen receptor …
including cancer. Cell therapy using fluorescent and radiolabeled chimeric antigen receptor …
[HTML][HTML] Modulation of the tumor microenvironment and mechanism of immunotherapy-based drug resistance in breast cancer
Breast cancer, the most frequent female malignancy, is often curable when detected at an
early stage. The treatment of metastatic breast cancer is more challenging and may be …
early stage. The treatment of metastatic breast cancer is more challenging and may be …
[HTML][HTML] Dendritic cells in cancer immunology and immunotherapy
L Hato, A Vizcay, I Eguren, JL Pérez-Gracia… - Cancers, 2024 - mdpi.com
Simple Summary Although immune check point inhibitors have been established as a new
paradigm in cancer treatment, they have shown no clinical benefit in immune excluded or …
paradigm in cancer treatment, they have shown no clinical benefit in immune excluded or …
[HTML][HTML] The Potential of Dendritic Cell Subsets in the Development of Personalized Immunotherapy for Cancer Treatment
AV Gorodilova, KV Kitaeva, IY Filin… - Current issues in …, 2023 - mdpi.com
Since the discovery of dendritic cells (DCs) in 1973 by Ralph Steinman, a tremendous
amount of knowledge regarding these innate immunity cells has been accumulating. Their …
amount of knowledge regarding these innate immunity cells has been accumulating. Their …
Application of Engineered Dendritic Cell Vaccines in Cancer Immunotherapy: Challenges and Opportunities
P Li, L Jia, X Bian, S Tan - Current Treatment Options in Oncology, 2023 - Springer
Opinion statement The primary objective of this study is to evaluate the effectiveness of
cancer vaccines containing genetically modified dendritic cells (DCs) in inducing …
cancer vaccines containing genetically modified dendritic cells (DCs) in inducing …
[HTML][HTML] Second-generation checkpoint inhibitors and Treg depletion synergize with a mouse cancer vaccine in accordance with tumor microenvironment …
W Becker, PB Olkhanud, N Seishima… - … for ImmunoTherapy of …, 2024 - ncbi.nlm.nih.gov
Background Despite advances in checkpoint inhibitor (CPI) therapy for cancer treatment,
many cancers remain resistant. Tumors deemed “cold” based on lack of T cell infiltration …
many cancers remain resistant. Tumors deemed “cold” based on lack of T cell infiltration …